Eva Dokoupilová

Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

Bente Langdahl, Cesar Libanati, Daria B. Crittenden et al. · The Lancet · 2017 · 450 citations

Bone Disease, Sclerostin, Bone Health +7

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial

Peter Nash, Bruce Kirkham, Masato Okada et al. · The Lancet · 2017 · 390 citations · Full text

Rheumatoid Disorder, Rheumatology, Spirit-p2 Phase 3 +12

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

Mark C. Genovese, Patrick Durez, Hanno B. Richards et al. · Annals of the Rheumatic Diseases · 2012 · 286 citations

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3

Karel Pavelka, Alan Kivitz, Eva Dokoupilová et al. · Arthritis Research & Therapy · 2017 · 227 citations · Full text

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

Philip J. Mease, Apinya Lertratanakul, J. Anderson et al. · Annals of the Rheumatic Diseases · 2020 · 224 citations · Full text